Journal
DRUG DISCOVERY TODAY
Volume 27, Issue 10, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2022.07.009
Keywords
Medicinal product; Medical device; Drug-device combination; Combination product; Integral product; Co-packaged product; Referenced products; Companion diagnostic
Categories
Ask authors/readers for more resources
The correct classification of combined medicinal products and medical devices is crucial for their development. Stakeholders in the European Union face obstacles due to lack of harmonization and divergent regulatory philosophies. In contrast, in the United States, stakeholders interact with a single authority, leading to more efficient issue resolution.
When a medicinal product (MP) and a medical device (MD) are combined, their correct classification implies discrimination among different possible scenarios, based on the nature of the combination and the principal mechanism of action. In the European Union (EU), stakeholders deal with a lack of harmonization, which can represent an obstacle toward the development of these products, and a complex nomenclature, emerging from two divergent regulatory philosophies (i.e., that of MPs and that of MDs). In the USA, where the US Food and Drug Administration (FDA) supervises MDs, drugs, and biological products, stakeholders interact with a single authority, where any issue is addressed internally.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available